HC Wainwright Issues Optimistic Estimate for MAZE Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Analysts at HC Wainwright upped their Q1 2026 earnings estimates for shares of Maze Therapeutics in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings per share of ($0.62) for the quarter, up from their prior estimate of ($0.73). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. HC Wainwright also issued estimates for Maze Therapeutics’ Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.57) EPS, FY2027 earnings at ($2.79) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.04) EPS and FY2030 earnings at $1.00 EPS.

MAZE has been the subject of several other research reports. Wedbush upped their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a report on Monday, March 16th. Truist Financial assumed coverage on Maze Therapeutics in a research report on Tuesday, March 17th. They issued a “buy” rating and a $68.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday. Finally, Guggenheim lifted their target price on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $64.11.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $31.71 on Friday. Maze Therapeutics has a one year low of $6.71 and a one year high of $53.65. The company’s fifty day moving average price is $45.81 and its 200-day moving average price is $37.51. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -9.82 and a beta of 4.47.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.

Institutional Trading of Maze Therapeutics

Large investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. raised its position in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after buying an additional 438,274 shares in the last quarter. Janus Henderson Group PLC grew its position in Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after acquiring an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. increased its stake in Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after acquiring an additional 362,060 shares during the last quarter. Woodline Partners LP increased its stake in Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after acquiring an additional 94,529 shares during the last quarter. Finally, Marshall Wace LLP raised its position in Maze Therapeutics by 9.0% during the fourth quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock valued at $35,111,000 after purchasing an additional 69,771 shares during the period.

Insider Activity

In related news, insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the sale, the insider owned 10,503 shares of the company’s stock, valued at $426,001.68. This represents a 87.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Harold Bernstein sold 45,000 shares of the company’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 245,000 shares of company stock worth $10,504,792.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply raised its price target to $110 and lifted EPS forecasts across 2026–2030, reiterating a “Buy” rating — a strong fundamental endorsement that supports upside expectations. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
• Positive Sentiment: BTIG reaffirmed a “Buy” rating (with a $46 target), providing additional analyst support following the trial news. Maze Therapeutics Earns “Buy” Rating from BTIG Research
• Positive Sentiment: Maze reported positive Phase 2 HORIZON topline data for MZE829, which the company and some analysts called the first clinical proof-of-concept in APOL1-mediated kidney disease — a major clinical milestone that underpins longer-term value. Phase 2 HORIZON topline data article
• Neutral Sentiment: An insider reported the sale of ~15,000 shares (executed via option exercise), disclosed publicly — a liquidity event that can be interpreted various ways but was not described as indicative of corporate problems. Insider sale disclosure
• Negative Sentiment: Despite the positive topline readout, investors sold heavily, and coverage noted the stock plunged roughly one-third at points on “mixed” midstage data interpretation — signaling investor concern about durability, subgroup results, or commercial assumptions. That volatility weighs on near-term price performance. Market reaction / mixed data article
• Negative Sentiment: Investor law firm Johnson Fistel announced an investigation into potential claims involving Maze executives, which can increase regulatory/legal risk and add selling pressure while inquiries are ongoing. Johnson Fistel investigation notice

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.